In recent conversations with mgt, this is definitely on their watchlist of priorities. US and Chinese deals need to be done this calendar year because:
1. Companies need time to do production forecasts, slot the activity into sales team calendars, prepare marketing and staff training materials.
2. We need cash to accelerate our next drug candidate DXB700 asap, or other orphan candidates for 200 to maintain premium pricing
3. Maintain liquidity above a certain level to be accepted into the indexes. This was specifically mentioned by Dimerix
Cheers.
DXB - Research & Valuation, page-49
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.015(3.80%) |
Mkt cap ! $228.4M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 41.5¢ | 39.0¢ | $1.181M | 2.922M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 260640 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 22838 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |